Lille (France), Cambridge (Massachusetts, United States), September 29, 2022 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the signing of the Share Purchase Agreement and the completion of its acquisition of Versantis AG (“Versantis”) under the terms announced in its press release on September 19, 2022.
Versant Ventures Launches Vector BioPharma AG
ZURICH--(BUSINESS WIRE)--Versantis, a clinical-stage biotechnology company developing novel therapies for orphan and pediatric liver diseases, today announced data showing both single and repeated intraperitoneal administrations of VS-01 reduced the concentration of several metabolites in the blood associated with infection-related acute-on-chronic liver failure (ACLF) and multiple organ failure (OF) related to ACLF. The data will be presented in two posters on Saturday June 25 at the International Liver Congress™ 2022. The abstract entitled ‘Metabolomic analysis of organ failure marker compounds in blood samples of patients with decompensated liver cirrhosis after administration of the novel drug VS-01’ was also selected for inclusion in the ‘Best of International Liver CongressTM 2022’.
ZURICH--(BUSINESS WIRE)-- Versantis,na clinical-stage biotechnology company developing novel therapies for norphan liver and pediatric diseases, today announced that positive Phasen1b clinical data from a study of its lead investigational, norphan-designated product, VS-01, in 12 hospitalized patients with ndecompensated liver cirrhosis will be presented at the American nAssociation for the Study of Liver Diseases (AASLD) annual meeting. The ndata show that VS-01 was safe and well tolerated in these patients, and ndemonstrated promising early indications of efficacy in this clinical nstudy. VS-01 is a potentially lifesaving, multi-organ support therapy nthat aims to timely reverse Acute-on-Chronic Liver Failure (ACLF) by nenhancing the clearance of ammonia and other toxins following nparacentesis.
ZURICH--(BUSINESS WIRE)--Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, today announced the appointment of Prof Dr Katharina Staufer as Chief Medical Officer. Prof Staufer is a gastroenterologist and hepatologist with a strong clinical and scientific background in metabolic liver disease, liver cirrhosis and transplant hepatology, including orphan liver diseases.
ZURICH--(BUSINESS WIRE)--Versantis AG, a clinical-stage company developing novel therapies for rare liver diseases and rare pediatric diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its lead product candidate VS-01 for the treatment of hyperammonemia (HA) in inborn errors of metabolism (IEM).
Versant Ventures today announced that portfolio company Vividion Therapeutics has been acquired by Bayer AG for $1.5 billion up front and up to $500 million in potential future milestone payments. This acquisition represents one of the largest transactions for a preclinical-stage biotechnology company.
Just under a year after securing its first venture round, a Versant-backed startup has pulled in a massive Series B haul to create designer cytokines —and it seems as though CEO Fredrik Wiklund is keeping the S-1 paperwork in his back pocket.
The well-funded venture capital firm Versant Ventures said Wednesday it has raised another $950 million to invest in biotechnology and healthcare companies.
ZURICH--(BUSINESS WIRE)-- Versantis, a clinical-stage company developing novel therapies for orphan liver and pediatric diseases, today announced positive results from a Phase 1b clinical trial of VS-01 in decompensated liver cirrhosis. VS-01 was found to be safe and well tolerated in this first-in-human, single ascending and multiple dose study led by Prof. Dr. Jonel Trebicka at the Goethe University Hospital Frankfurt. VS-01 is a potentially lifesaving, multi-organ support therapy that aims to reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and other toxins from the body.